Ozempic compounding ban no ‘knee-jerk’ reaction

Department defends recommendation to ban the compounding of semaglutide and tirepatide medications  Moves to prohibit pharmacists from compounding replicas of Ozempic (semaglutide) and Mounjaro (tirepatide) were not a “knee-jerk response” to a story by the ABC, a Department of Health and Aged Care official says.  Speaking during a Senate Estimates hearing earlier this month (5

This content is restricted to registered users only. If you have already registered on the AJP website please login below, Or you can Register for free.

Forgot Password?Why do I need to login & stay in?

Previous Could CWH/Sigma merger prompt retail pharmacy foreclosures?
Next The link between acne and diet: where are we now?